Volitionrx LTD (VNRX) — 10-Q Filings

10-Q Filings (6)

• VolitionRx Narrows Losses Amid Revenue Growth, Cash Dries Up — Nov 13, 2025 Risk: high
  VolitionRx Limited reported a net loss of $17,200,488 for the nine months ended September 30, 2025, a 19.6% improvement from the $21,400,758 net loss in the pri
• VolitionRx Narrows Losses Amid Revenue Growth, R&D Cuts — Aug 14, 2025 Risk: high
  VolitionRx Limited (VNRX) reported a net loss of $11,790,697 for the six months ended June 30, 2025, a significant improvement from the $15,532,180 net loss in
• VolitionRx Ltd. Q1 2025 10-Q: Assets $175M, Equity $96.1M — May 15, 2025 Risk: medium
  VolitionRx Ltd. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $175 million and total liabilities of $100.7 million,
• VolitionRx Ltd. Q3 2024 10-Q Filed — Nov 14, 2024 Risk: medium
  VolitionRx Ltd. filed its Q3 2024 10-Q report on November 14, 2024, covering the period ending September 30, 2024. The company reported total assets of $175 mil
• VolitionRx Ltd. Files Q2 2024 10-Q, Details Financials — Aug 14, 2024 Risk: medium
  VolitionRx Ltd. filed its 10-Q for the period ending June 30, 2024, reporting a net loss. The company's financial statements indicate a decrease in cash and cas
• VolitionRx Ltd. Files 10-Q for Q1 2024 — May 13, 2024 Risk: low
  VOLITIONRX LTD (VNRX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. VolitionRx Ltd. reported financial results for the first quarter ended March

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX